TG Therapeutics Inc TGTX
News
TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
TG Therapeutics to Participate in the Cantor Global Healthcare Conference
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance
These under-the-radar stocks combine fast growth with big upside potential


